
Aymeric Menard Appointed as Managing Director of Servier Philippines
14/03/2025
thousand employees
countries in which the Group’s
medicines are distributed 20%
of revenue from brand-name
medicines invested in R&D
each year
euros in revenue in 2023/2024 including
€4.5 billion for brand-name medicines
and €1.4 billion for generic activities
Oncology, Cardiometabolism &
Venous Diseases, Neurology